Mandate

Vinge advises Calliditas Therapeutics in connection with the listing on Nasdaq Stockholm’s main market

Vinge advises Calliditas Therapeutics AB (publ) (“Calliditas Therapeutics”) in connection with the listing of the company’s shares on Nasdaq Stockholm’s main market. Trading in Calliditas Therapeutics’ shares on Nasdaq Stockholm commences today, 29 June 2018.

The price in the offering was set at SEK 45 per share, which corresponds to a value of the total number of shares in the company upon completion of the offering of SEK 1,593 million, assuming full exercise of the over-allotment option in the offering. Assuming full exercise of the over-allotment option, the value of the offering amounts to approximately SEK 747 million before transaction costs. 

Calliditas is a specialty pharmaceutical company based in Stockholm, Sweden, focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications in which the company can partially or completely participate in the commercialization efforts. The company is focused on the development and commercialization of the product candidate Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy.
  
Vinge’s team primarily consists of Dain Hård Nevonen, Johan Larsson, Maria Schultzberg, Sofie Bjärtun, Sabina Kihlberg, Filip Öhrner, Victor Ericsson and William Kåge. 

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025